サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：医薬品薬事の世界市場レポート：産業分析、規模、シェア、成長、動向、予測（2023年～2030年）
市場調査レポート
商品コード
1377862

医薬品薬事の世界市場レポート：産業分析、規模、シェア、成長、動向、予測（2023年～2030年）

Global Pharmaceutical Regulatory Affairs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 235 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
医薬品薬事の世界市場レポート：産業分析、規模、シェア、成長、動向、予測（2023年～2030年）
出版日: 2023年09月01日
発行: Value Market Research
ページ情報: 英文 235 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医薬品薬事の世界需要は、2023年～2030年の調査期間中にCAGR8.4%で成長し、2022年の92億3,000万米ドルから2030年には176億米ドル近くの市場規模に達すると推定されます。

製薬業界では単に薬事（Regulatory Affairs：RA）と呼ばれることが多い医薬品薬事規制は、製薬会社やバイオテクノロジー企業が医薬品や医療製品の開発、製造、試験、マーケティング、流通を管理するすべての関連規制や法律を遵守することを保証する重要な機能です。この分野は、安全で効果的な医薬品やヘルスケア製品を市場に送り出すと同時に、ライフサイクルを通じて規制基準を遵守し続けるという中心的な役割を担っています。

市場力学：

医薬品薬事は、製薬業界とその規制状況のダイナミックな性質を反映するいくつかの重要な要因によって推進されています。医薬品の開発と市場開拓を管理する規則や要件は刻々と変化しており、製薬企業やバイオテクノロジー企業では強固な薬事業務機能が必要とされています。医薬品開発の世界化、新薬と治療法の絶え間ない出現、安全性と品質基準の厳格な重視は、主要な促進要因です。生物学的製剤、バイオシミラー、ジェネリック医薬品の台頭は、複雑な承認プロセスをナビゲートする専門知識を必要とするユニークな規制上の課題を提示しています。薬事業務の専門家は、技術の進歩への適応、COVID-19パンデミックのような世界ヘルスの懸念への対応、データの透明性とコンプライアンスの確保を支援します。ヘルスケア改革、特許切れ、患者中心のアプローチの増加は、製薬業務における薬事業務の重要性をさらに強調しています。これらの要因の総体として、複雑な規制状況の中で製薬会社を導き、医薬品と治療法の安全性、有効性、そして世界中の多様で進化する規制へのコンプライアンスを確保する薬事業務の重要な役割が浮き彫りになっています。業界が進化と拡大を続ける中、薬事部門は医薬品の成功と革新の最前線にあり続けています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは医薬品薬事の世界市場における各セグメントを包括的に評価することもできます。医薬品薬事の成長と動向は、本調査に全体的なアプローチを提供します。

地域分析：

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける医薬品薬事市場の現在および将来の需要を強調する地域展望をカバーします。さらに、このレポートでは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 医薬品薬事 - 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 医薬品薬事の世界市場分析：サービス別

  • 概要：サービス別
  • 実績データと予測データ
  • 分析：サービス別
  • 薬事コンサルティング
  • 法的代理
  • レギュラトリーライティング・パブリッシング（執筆、出版）
  • 製品登録および臨床試験申請
  • その他のサービス

第6章 医薬品薬事の世界市場分析：カテゴリー別

  • 概要：カテゴリー別
  • 実績データと予測データ
  • 分析：カテゴリー別
  • 医薬品（イノベーター、ジェネリック医薬品）
  • 生物製剤（バイオテクノロジー、ATMP、バイオシミラー）

第7章 医薬品薬事の世界市場分析：適応症別

  • 概要：適応症別
  • 実績データと予測データ
  • 分析：適応症別
  • がん領域
  • 神経学
  • 循環器
  • 免疫学
  • その他

第8章 医薬品薬事の世界市場分析：製品ステージ別

  • 概要：製品ステージ別
  • 実績データと予測データ
  • 分析：製品ステージ別
  • 前臨床試験
  • 臨床試験
  • PMA

第9章 医薬品薬事の世界市場分析：サービスプロバイダー別

  • 概要：サービスプロバイダー別
  • 実績データと予測データ
  • 分析：サービスプロバイダー別
  • インハウス
  • アウトソーシング

第10章 医薬品薬事の世界市場分析：企業規模別

  • 概要：企業規模別
  • 実績データと予測データ
  • 分析：企業規模別
  • 小規模
  • 中規模
  • 大規模

第11章 医薬品薬事の世界市場分析：地域別

  • 地域別の展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第12章 医薬品薬事企業の競合状況

  • 医薬品薬事市場の競合
  • 提携/協力/合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第13章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Freyr
  • IQVIA Inc.
  • ICON plc
  • WuXi AppTec
  • Charles River Laboratories
  • Labcorp Drug Development
  • Parexel International Corporation
  • Pharmalex GmbH
  • Pharmexon
  • Genpact
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Services (USD MN)
  • Regulatory Consulting Market Sales by Geography (USD MN)
  • Legal Representation Market Sales by Geography (USD MN)
  • Regulatory Writing & Publishing (Writing, Publishing) Market Sales by Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales by Geography (USD MN)
  • Other Services Market Sales by Geography (USD MN)
  • Analysis Market by Category (USD MN)
  • Drugs (Innovator, Generics) Market Sales by Geography (USD MN)
  • Biologics (Biotech, ATMP, Biosimilars) Market Sales by Geography (USD MN)
  • Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Product Stage (USD MN)
  • Preclinical Market Sales by Geography (USD MN)
  • Clinical studies Market Sales by Geography (USD MN)
  • PMA Market Sales by Geography (USD MN)
  • Analysis by Service Provider (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourcing Market Sales by Geography (USD MN)
  • Analysis by Company Size (USD MN)
  • Small Market Sales by Geography (USD MN)
  • Medium Market Sales by Geography (USD MN)
  • Large Market Sales by Geography (USD MN)
  • Global Pharmaceutical Regulatory Affairs Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Pharmaceutical Regulatory Affairs Report
  • Market Research Process
  • Market Research Methodology
  • Global Pharmaceutical Regulatory Affairs Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Services
  • Market Attractiveness Analysis by Category
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Product Stage
  • Market Attractiveness Analysis by Service Provider
  • Market Attractiveness Analysis by Company Size
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Services (USD MN)
  • Regulatory Consulting Market Sales by Geography (USD MN)
  • Legal Representation Market Sales by Geography (USD MN)
  • Regulatory Writing & Publishing (Writing, Publishing) Market Sales by Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales by Geography (USD MN)
  • Other Services Market Sales by Geography (USD MN)
  • Global Market Analysis by Category (USD MN)
  • Drugs (Innovator, Generics) Market Sales by Geography (USD MN)
  • Biologics (Biotech, ATMP, Biosimilars) Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Product Stage (USD MN)
  • Preclinical Market Sales by Geography (USD MN)
  • Clinical studies Market Sales by Geography (USD MN)
  • PMA Market Sales by Geography (USD MN)
  • Global Market Analysis by Service Provider (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourcing Market Sales by Geography (USD MN)
  • Global Market Analysis by Company Size (USD MN)
  • Small Market Sales by Geography (USD MN)
  • Medium Market Sales by Geography (USD MN)
  • Large Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112255

The global demand for Pharmaceutical Regulatory Affairs Market is presumed to reach the market size of nearly USD 17.6 BN by 2030 from USD 9.23 BN in 2022 with a CAGR of 8.4% under the study period 2023 - 2030.

Pharmaceutical regulatory affairs, often simply referred to as Regulatory Affairs (RA) in the pharmaceutical industry, is a critical function responsible for ensuring that pharmaceutical and biotechnology companies comply with all relevant regulations and laws governing the development, manufacturing, testing, marketing, and distribution of drugs and medical products. This field plays a central role in bringing safe and effective medications and healthcare products to market while ensuring that they remain in compliance with regulatory standards throughout their lifecycle.

MARKET DYNAMICS:

The Pharmaceutical regulatory affairs market is propelled by several critical factors that reflect the dynamic nature of the pharmaceutical industry and its regulatory landscape. The ever-changing rules and requirements governing drug development and marketing necessitate a robust Regulatory Affairs function within pharmaceutical and biotechnology companies. Globalization of drug development, the continuous emergence of new drugs and therapies, and the stringent emphasis on safety and quality standards are key drivers. The rise of biologic drugs, biosimilars, and generic medications presents unique regulatory challenges that demand expertise in navigating complex approval processes. Regulatory Affairs professionals assist in adapting to technological advances, addressing global health concerns like the COVID-19 pandemic, and ensuring data transparency and compliance. Healthcare reforms, patent expirations, and the growth of patient-centric approaches further underscore the significance of Regulatory Affairs in pharmaceutical operations. These factors collectively underscore the critical role of Regulatory Affairs in guiding pharmaceutical companies through the intricate regulatory landscape, ensuring that drugs and therapies are safe, effective, and compliant with diverse and evolving regulations worldwide. As the industry continues to evolve and expand, Regulatory Affairs remains at the forefront of pharmaceutical success and innovation.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pharmaceutical regulatory affairs. The growth and trends of pharmaceutical regulatory affairs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pharmaceutical regulatory affairs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Services

  • Regulatory Consulting
  • Legal Representation
  • Regulatory Writing & Publishing (Writing, Publishing)
  • Product Registration & Clinical Trial Applications
  • Other Services

By Category

  • Drugs (Innovator, Generics)
  • Biologics (Biotech, ATMP, Biosimilars)

By Indication

  • Oncology
  • Neurology
  • Cardiology
  • Immunology
  • Others

By Product Stage

  • Preclinical
  • Clinical Studies
  • PMA

By Service Provider

  • In-House
  • Outsourcing

By Company Size

  • Small
  • Medium
  • Large

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pharmaceutical Regulatory Affairs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmaceutical Regulatory Affairs market include Freyr, IQVIA Inc., ICON plc, WuXi AppTec, Charles River Laboratories, Labcorp Drug Development, Parexel International Corporation, Pharmalex GmbH, Pharmexon, Genpact. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PHARMACEUTICAL REGULATORY AFFAIRS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Services
    • 3.7.2 Market Attractiveness Analysis By Category
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By Product Stage
    • 3.7.5 Market Attractiveness Analysis By Service Provider
    • 3.7.6 Market Attractiveness Analysis By Company Size
    • 3.7.7 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICES

  • 5.1 Overview by Services
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Services
  • 5.4 Regulatory Consulting Historic and Forecast Sales by Regions
  • 5.5 Legal Representation Historic and Forecast Sales by Regions
  • 5.6 Regulatory Writing & Publishing (Writing, Publishing) Historic and Forecast Sales by Regions
  • 5.7 Product Registration & Clinical Trial Applications Historic and Forecast Sales by Regions
  • 5.8 Other Services Historic and Forecast Sales by Regions

6 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY CATEGORY

  • 6.1 Overview by Category
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Category
  • 6.4 Drugs (Innovator, Generics) Historic and Forecast Sales by Regions
  • 6.5 Biologics (Biotech, ATMP, Biosimilars) Historic and Forecast Sales by Regions

7 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Oncology Historic and Forecast Sales by Regions
  • 7.5 Neurology Historic and Forecast Sales by Regions
  • 7.6 Cardiology Historic and Forecast Sales by Regions
  • 7.7 Immunology Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY PRODUCT STAGE

  • 8.1 Overview by Product Stage
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Product Stage
  • 8.4 Preclinical Historic and Forecast Sales by Regions
  • 8.5 Clinical studies Historic and Forecast Sales by Regions
  • 8.6 PMA Historic and Forecast Sales by Regions

9 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICE PROVIDER

  • 9.1 Overview by Service Provider
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Service Provider
  • 9.4 In-house Historic and Forecast Sales by Regions
  • 9.5 Outsourcing Historic and Forecast Sales by Regions

10 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY COMPANY SIZE

  • 10.1 Overview by Company Size
  • 10.2 Historical and Forecast Data
  • 10.3 Analysis by Company Size
  • 10.4 Small Historic and Forecast Sales by Regions
  • 10.5 Medium Historic and Forecast Sales by Regions
  • 10.6 Large Historic and Forecast Sales by Regions

11 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Regional Outlook
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.3.2. North America By Segment Sales Analysis
    • 11.3.3. North America By Country Sales Analysis
    • 11.3.4. United State Sales Analysis
    • 11.3.5. Canada Sales Analysis
    • 11.3.6. Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.4.2. Europe by Segment Sales Analysis
    • 11.4.3. Europe by Country Sales Analysis
    • 11.4.4. United Kingdom Sales Analysis
    • 11.4.5. France Sales Analysis
    • 11.4.6. Germany Sales Analysis
    • 11.4.7. Italy Sales Analysis
    • 11.4.8. Russia Sales Analysis
    • 11.4.9. Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.5.2. Asia Pacific by Segment Sales Analysis
    • 11.5.3. Asia Pacific by Country Sales Analysis
    • 11.5.4. China Sales Analysis
    • 11.5.5. India Sales Analysis
    • 11.5.6. Japan Sales Analysis
    • 11.5.7. South Korea Sales Analysis
    • 11.5.8. Australia Sales Analysis
    • 11.5.9. South East Asia Sales Analysis
    • 11.5.10. Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.6.2. Latin America by Segment Sales Analysis
    • 11.6.3. Latin America by Country Sales Analysis
    • 11.6.4. Brazil Sales Analysis
    • 11.6.5. Argentina Sales Analysis
    • 11.6.6. Peru Sales Analysis
    • 11.6.7. Chile Sales Analysis
    • 11.6.8. Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.7.2. Middle East & Africa by Segment Sales Analysis
    • 11.7.3. Middle East & Africa by Country Sales Analysis
    • 11.7.4. Saudi Arabia Sales Analysis
    • 11.7.5. UAE Sales Analysis
    • 11.7.6. Israel Sales Analysis
    • 11.7.7. South Africa Sales Analysis
    • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL REGULATORY AFFAIRS COMPANIES

  • 12.1. Pharmaceutical Regulatory Affairs Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13 . COMPANY PROFILES OF PHARMACEUTICAL REGULATORY AFFAIRS INDUSTRY

  • 13.1. Company Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. Freyr
    • 13.3.1. Company Overview
    • 13.3.2. Company Revenue
    • 13.3.3. Products
    • 13.3.4. Recent Developments
  • 13.4. IQVIA Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Company Revenue
    • 13.4.3. Products
    • 13.4.4. Recent Developments
  • 13.5. ICON plc
    • 13.5.1. Company Overview
    • 13.5.2. Company Revenue
    • 13.5.3. Products
    • 13.5.4. Recent Developments
  • 13.6. WuXi AppTec
    • 13.6.1. Company Overview
    • 13.6.2. Company Revenue
    • 13.6.3. Products
    • 13.6.4. Recent Developments
  • 13.7. Charles River Laboratories
    • 13.7.1. Company Overview
    • 13.7.2. Company Revenue
    • 13.7.3. Products
    • 13.7.4. Recent Developments
  • 13.8. Labcorp Drug Development
    • 13.8.1. Company Overview
    • 13.8.2. Company Revenue
    • 13.8.3. Products
    • 13.8.4. Recent Developments
  • 13.9. Parexel International Corporation
    • 13.9.1. Company Overview
    • 13.9.2. Company Revenue
    • 13.9.3. Products
    • 13.9.4. Recent Developments
  • 13.10. Pharmalex GmbH
    • 13.10.1. Company Overview
    • 13.10.2. Company Revenue
    • 13.10.3. Products
    • 13.10.4. Recent Developments
  • 13.11. Pharmexon
    • 13.11.1. Company Overview
    • 13.11.2. Company Revenue
    • 13.11.3. Products
    • 13.11.4. Recent Developments
  • 13.12. Genpact
    • 13.12.1. Company Overview
    • 13.12.2. Company Revenue
    • 13.12.3. Products
    • 13.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies